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ABSTRACT
Introduction: Combining long-acting
muscarinic antagonists (LAMAs) and
long-acting b2-agonists (LABAs) is beneficial in
chronic obstructive pulmonary disease (COPD),
as the two classes of bronchodilator have
complementary modes of action. The optimal
dose for the fixed-dose combination of the
LAMA tiotropium and the LABA olodaterol
needed to be determined. In this phase II trial,
the dose response of tiotropium on top of
olodaterol was investigated in a free-dose
combination, while other phase II studies have
explored different doses of olodaterol on top of
tiotropium, with both drugs delivered using the
Respimat inhaler.
Methods: This was a double-blind incomplete
crossover trial in which 233 patients with
moderate or severe COPD were randomized to
receive four out of eight free-dose combinations
of olodaterol (5 or 10 lg) and tiotropium (1.25,
2.5, or 5 lg) or placebo for 4 weeks each.
Primary end point was trough forced
expiratory volume in 1 s (FEV1) change from
baseline (response) after 4 weeks.
Results: Addition of tiotropium 1.25, 2.5, and
5 lg to olodaterol 5 lg increased mean trough
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FEV1 response by 0.054, 0.065, and 0.084 L,
respectively; addition of tiotropium 1.25, 2.5,
and 5 lg to olodaterol 10 lg increased mean
trough FEV1 response by 0.051, 0.083, and
0.080 L, respectively. All treatments were well
tolerated and incidence of adverse events was
similar with all treatments.
Conclusions: Overall, a dose response for
tiotropium on top of both doses of olodaterol
was observed, with increasing improvements in
trough FEV1 compared to olodaterol alone as
the tiotropium dose was increased.
Funding: Boehringer Ingelheim.
Trial registration: ClinicalTrials.gov number,
NCT01040403.
Keywords: Bronchodilator; Chronic obstructive
pulmonary disease; Dose finding; Long-acting
b2-agonists; Long-acting muscarinic antagonists;
Olodaterol; Tiotropium
INTRODUCTION
The two main classes of bronchodilator used in
chronic obstructive pulmonary disease (COPD) are
long-acting muscarinic antagonists (LAMAs) and
long-acting b2-agonists (LABAs), and use of
LAMA ? LABA combination in COPD is
supported by international guidelines [1].
Combining bronchodilators with complementary
modes of action in COPD offers greater lung
function benefits than individual agents, with
similar tolerability and safety [2, 3]. A number of
LAMA/LABA fixed-dose combinations (FDCs) are
now available or in development for the treatment
of COPD, and these combinations have shown
improvements in lung function, exercise
tolerance, and patient-reported outcomes
compared to individual agents [3].
Tiotropium is a well-established, once-daily
LAMA for the maintenance treatment of COPD
[4]. Olodaterol is a once-daily LABA with high
b2 selectivity and a fast onset of action [5, 6]
that has demonstrated efficacy and tolerability
in phase III trials [7–10] and has been approved
for use in COPD in the US, Europe, and several
other countries. A clinical program
investigating the efficacy and safety of the
FDC of tiotropium ? olodaterol has been
completed, and the FDC has been approved in
the US and Canada for the treatment of COPD.
Often when combining drugs in an FDC, it is
assumed that the optimal doses should reflect
those of the registered components, although
this may not always be the case [11]. Prior to the
phase III program for the tiotropium ?
olodaterol FDC, a novel approach was taken to
test this assumption and a series of phase II
dose–response trials was developed to
determine the dose response of each
component within the FDC.
Two phase II studies (1237.4 [NCT00696020]
and 1237.9 [NCT00720499]) investigated
different doses of olodaterol 2–10 lg (1237.9: 2
or 5 lg; 1237.4: 2, 5, or 10 lg) when added to
tiotropium 5 lg, compared to tiotropium
monotherapy [12]. In the study presented here,
the dose response of tiotropium when added to
olodaterol as a free-dose combination was
investigated to determine the doses to be
studied in the phase III tiotropium ? olodaterol
trials. Tiotropium 1.25, 2.5, and 5 lg were added
to olodaterol 5 and 10 lg in free combination.
The doses of tiotropium were chosen to provide
a robust evaluation of the most relevant part of
its dose–response curve and the highest dose
included—5 lg—is its licensed dose in the
Respimat inhaler as monotherapy. In this
study, a free combination of tiotropium and
olodaterol (i.e., using a separate Respimat device
for each treatment rather than the combination
of treatments being delivered via one device) was
used rather than the FDC because an FDC for the
lower dose of tiotropium was not available.
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The objective of the study reported here was
to identify the optimal once-daily doses of
tiotropium and olodaterol administered in free
combination via the Respimat inhaler in COPD




This was a randomized, double-blind, phase IIb,
incomplete crossover trial (ClinicalTrials.gov
#NCT01040403; 1237.18) conducted between
February 2010 and February 2011. Patients were
randomized to receive four out of eight
combinations: olodaterol (5 or 10 lg) in
combination with tiotropium (1.25, 2.5, or
5 lg) or placebo (in place of tiotropium) for
4 weeks each in a randomized order (Fig. 1).
There was a washout period before screening
and, following the screening visit, there was a
2-week run-in period prior to randomization to
ensure clinical stability. In between each
treatment period, there were 3-week washout
periods and patients were evaluated for 3 weeks
following the final dose of the last treatment.
The trial was carried out in compliance with
the Declaration of Helsinki (1964, as revised in
2008), in accordance with the International
Conference on Harmonisation Harmonised
Tripartite Guideline for Good Clinical Practice
and local regulations. Written, informed
consent was obtained from all patients.
Patients
Patients aged C40 years with COPD and a
smoking history of[10 pack-years could be
recruited if they had a post-bronchodilator
forced expiratory volume in 1 s (FEV1)
of C30% and\80% of the predicted normal
and a post-bronchodilator FEV1/forced vital
capacity (FVC) of\70% at screening (Global
Fig. 1 Trial design
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initiative for chronic Obstructive Lung Disease
[GOLD] 2–3). Exclusion criteria included a
significant disease other than COPD, history of
asthma, history of myocardial infarction within
the previous year, clinically relevant cardiac
arrhythmia, paroxysmal tachycardia, and
history of life-threatening pulmonary
obstruction.
Patients continued to take inhaled
corticosteroids throughout the trial, if used
prior to study entry as maintenance therapy.
During run-in, washout, and post-treatment
follow-up periods, LABAs and short-acting
muscarinic antagonists were permitted, with a
48-h washout for LABAs and an 8-h washout for
short-acting muscarinic antagonists before
pulmonary function testing. LAMAs other
than study drug were only permitted during
the follow-up period and the short-acting
b2-agonist salbutamol was provided as rescue
medication for use throughout the trial.
Treatments
Tiotropium (or placebo) and olodaterol were
provided in two separate Respimat inhalers.
Patients were to inhale two puffs of each of the
assigned Respimat inhalers every morning
between 7.00 A.M. and 10.00 A.M. On study
visit days, patients were to inhale the study drug
at the clinic instead of at home. Patients
recorded whether they took the medication in
a diary.
Assessments
Pulmonary function tests were performed at
screening, on Day 1 of each treatment period (at
1 h pre-dose and 10 min pre-dose, 5 and 30 min
post-dose, and 1, 2, and 3 h post-dose), after
4 weeks of each treatment (at same time points
as Day 1 plus at 4, 5, and 6 h post-dose), and at
follow-up. At each time point, spirometric
measurements were performed in triplicate,
and the highest FEV1 and FVC values were
recorded. Spirometers and their use, including
daily calibration, were to meet American
Thoracic Society and European Respiratory
Society criteria.
Patients recorded the number of puffs of
rescue medication they took during the day and
at night in a diary. Patient’s global rating was
assessed at the end of each treatment period
(before spirometry); patients rated their own
respiratory health compared to the day before
commencing each treatment period on a
7-point scale from ‘‘very much better’’ (1) to
‘‘very much worse’’ (7). Physician’s global
evaluation was assessed on the first and last
day of each treatment period; the investigator
rated the patient’s overall clinical condition
from ‘‘poor’’ (1–2) to ‘‘excellent’’ (7–8).
All adverse events (AEs) were recorded at
each visit. Clinical laboratory testing was
conducted at screening and at the end of each
treatment period, and a standard 12-lead
electrocardiogram was performed at screening
and at all treatment visits 30 and 40 min
post-dose. Any abnormalities or worsening of
baseline conditions were reported as AEs.
Study Outcomes
The primary end point was trough FEV1
response (change from baseline) after 4 weeks
of treatment. Trough FEV1 was defined as the
mean of the two pre-treatment FEV1 values (at
1 h and 10 min before dosing, respectively) at
the end of the dosing interval, and baseline
FEV1 was defined as the mean of the two
pre-treatment FEV1 values (1 h pre-dose and
10 min pre-dose) measured prior to
administration of the first dose of study
medication.
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Secondary end points included trough FVC,
FEV1, and FVC area under the curve from 0 to
6 h (AUC0–6), mean weekly rescue medication
use, physician’s global evaluation, and patient’s
global rating. Incidence and severity of AEs were
reported irrespective of causality, and pulse rate
and blood pressure were recorded in
conjunction with spirometry at 10 min
pre-dose and 30 min post-dose.
Statistical Analysis
To detect a treatment difference of 0.050 L in
trough FEV1 with 90% power, assuming a
standard deviation of 0.140 L, 85 patients were
required to complete the study (based on a
complete crossover design). To determine the
number of patients required for the
incomplete-block design used in this trial, the
equation n = 7 m/3 was used, where m is the
number of patients required for a complete
crossover study. Allowing for a discontinuation
rate of 12%, 224 patients needed to be
randomized.
The full analysis set was defined as treated
patients who provided baseline data and at least
one on-treatment value for the primary end
point after 4 weeks of treatment. This set of
patients was used for all efficacy analyses
presented here.
Comparison between treatment groups for
the primary and secondary end points was
based on a mixed-effect repeated measures
model including treatment and period as fixed
effects, patient as a random effect, and (study)
baseline as a covariate. Adjusted mean values
and treatment comparisons are presented with
corresponding 95% confidence intervals.
Statistical analysis was carried out using SAS
version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient Disposition and Baseline
Characteristics
In total, 283 patients were enrolled into the
study and 233 were randomized to treatment.
One randomized patient was withdrawn before
receiving any medication due to an episode
of atrial fibrillation. Overall, 91.8% of
patients completed all four assigned
treatments (Fig. 2).
Patient demographics and baseline
characteristics are shown in Table 1; 37.5% of
patients were GOLD 2 and 59.9% were GOLD 3.
Most patients were taking pulmonary
medications in the 3 months prior to screening
(91.4%), most commonly LABAs, short-acting
b2-agonists, inhaled corticosteroids, and LAMAs
(Table 1). The most common concomitant
diagnoses were hypertension (41.4%) and
hypercholesterolemia (18.1%); all other
concomitant diagnoses had an incidence\10%.
Efficacy
Lung Function
Trough FEV1 responses with olodaterol 5 and
10 lg were 0.071 and 0.083 L, respectively, after
4 weeks of treatment. Trough FEV1 responses
increased with tiotropium ? olodaterol doses
compared to olodaterol monotherapy after
4 weeks of treatment. Compared to olodaterol
5 lg monotherapy, the addition of tiotropium
1.25, 2.5, and 5 lg increased trough FEV1
response by 0.054, 0.065, and 0.084 L,
respectively, and compared to olodaterol
10 lg, the addition of tiotropium 1.25, 2.5,
and 5 lg increased trough FEV1 by 0.051, 0.083,
and 0.080 L, respectively (Table 2).
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The FEV1 profiles after 4 weeks of treatment
showed clear improvements with tiotropium ?
olodaterol compared to olodaterol monotherapy
and improvements in FEV1 with increasing
tiotropium doses on top of olodaterol 5 and
10 lg (Fig. 3). FEV1 AUC0–6 responses
showed incremental increases with increasing
dose of tiotropium with both olodaterol
doses (Table 2). The additional benefits from
adding each dose of tiotropium to olodaterol
were larger for FEV1 AUC0–6 than for trough FEV1
although, in both cases, FEV1 response was
greater overall with the combination therapy
compared to olodaterol (Table 2).
The FVC profiles showed improvements with
the addition of tiotropium to both olodaterol
doses (Fig. 4) and FVC AUC0–6 and trough FVC
results showed greater improvements with
tiotropium ? olodaterol compared to olodaterol
alone. Tiotropium added to olodaterol 5 lg
showed increases in trough FVC between 0.099
and 0.120 L compared to olodaterol 5 lg, while
tiotropium added to olodaterol 10 lg increased
trough FVC by 0.127–0.131 L. FVC AUC0–6 also
increased with the addition of tiotropium 1.25,
2.5, and 5 lg compared to olodaterol 5 lg alone
by 0.131–0.150 L, and added to olodaterol 10 lg
by 0.179–0.213 L (Table 3).
Other Secondary End Points
Weekly mean rescue medication use decreased
from baseline levels with all treatments after
4 weeks, with no notable differences between
treatment arms. Mean number of puffs per day
were 1.4, 1.5, 1.3, and 1.4 with olodaterol 5 lg,
tiotropium ? olodaterol 1.25/5, 2.5/5, and
5/5 lg, respectively, and 1.6, 1.3, 1.2, and
1.3 puffs per day with olodaterol 10 lg,
tiotropium ? olodaterol 1.25/10, 2.5/10, and
5/10 lg, respectively. Daytime and nighttime
rescue medication use was also decreased with all
treatments (Table S1 in the supplementary
material).
There were improvements compared to
baseline in physician’s global evaluation after
4 weeks in all treatment arms, with the smallest
increases with olodaterol monotherapies
(Table S2 in the supplementary material).
Patients generally rated their health as ‘‘a little
better’’ on the patient’s global rating after
Fig. 2 Patient disposition
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4 weeks across treatment arms (Table S2 in the
supplementary material).
Safety
AEs are summarized in Table 4; the most
common were nasopharyngitis and COPD
exacerbation. AEs leading to discontinuation
occurred in\2% of patients with any treatment.
The incidence of serious AEs is presented in
Table 4; two patients died during the washout
period following olodaterol 10 lg treatment.
Both deaths were caused by myocardial
infarction and were not considered by
investigators to be related to study drug.
Across treatment arms, incidence of AEs was
similar, with no increase in AEs for
tiotropium ? olodaterol versus olodaterol or
with increasing doses of tiotropium. There
were no notable changes in vital signs with
any treatment.
DISCUSSION
This trial demonstrated that the combination of
tiotropium ? olodaterol delivered via the
Respimat inhaler resulted in greater




Male, n (%) 133 (57.3)
Mean (SD) age, years 63.3 (8.2)
Smoking status, n (%)
Ex-smoker 125 (53.9)
Current smoker 107 (46.1)
Mean (SD) smoking history, pack-years 41.6 (19.4)
Mean (SD) pre-bronchodilator FEV1, L 1.379 (0.482)
Mean (SD) post-bronchodilator
FEV1, L 1.551 (0.499)
% predicted normal FEV1 55.03 (13.12)
FEV1/FVC, % 50.99 (10.34)
Mean (SD) change from pre- to
post-bronchodilator FEV1, L
0.172 (0.143)







Concomitant diagnoses with incidence[10%, n (%)
Hypertension 96 (41.4)
Hypercholesterolemia 42 (18.1)













FEV1 forced expiratory volume in 1 s, FVC forced vital
capacity, GOLD Global initiative for chronic Obstructive
Lung Disease, ICS inhaled corticosteroid, LABA
long-acting b2-agonist, LAMA long-acting muscarinic
antagonist, SAMA short-acting muscarinic antagonist,
SABA short-acting b-agonist, SD standard deviation
a Only salbutamol permitted during treatment periods as
rescue medication
b Patients permitted to continue during treatment periods
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improvements in lung function than olodaterol
monotherapy, as shown by trough FEV1
(primary end point) after 4 weeks of treatment.
Dose-related increases in trough FEV1 were
observed with increasing doses of tiotropium
on top of both doses of olodaterol, and














O 5 lg 0.071 (0.018) 0.188 (0.020)
?T 1.25 lg 0.125 (0.018) 0.054 (0.016, 0.092) 0.0057 0.267 (0.020) 0.078 (0.040, 0.117) \0.0001
?T 2.5 lg 0.136 (0.018) 0.065 (0.027, 0.103) 0.0009 0.287 (0.020) 0.099 (0.060, 0.137) \0.0001
?T 5 lg 0.155 (0.018) 0.084 (0.046, 0.122) \0.0001 0.307 (0.020) 0.118 (0.080, 0.157) \0.0001
O 10 lg 0.083 (0.018) 0.198 (0.020)
?T 1.25 lg 0.134 (0.018) 0.051 (0.013, 0.089) 0.0092 0.296 (0.020) 0.098 (0.060, 0.136) \0.0001
?T 2.5 lg 0.166 (0.018) 0.083 (0.045, 0.122) \0.0001 0.320 (0.020) 0.121 (0.083, 0.159) \0.0001
?T 5 lg 0.163 (0.018) 0.080 (0.042, 0.119) \0.0001 0.342 (0.020) 0.144 (0.105, 0.182) \0.0001
AUC0–6 area under the curve from 0 to 6 h, CI conﬁdence interval, FEV1 forced expiratory volume in 1 s, O olodaterol,
SE standard error, T tiotropium
Fig. 3 FEV1 proﬁles after 4 weeks of treatment with
tiotropium 1.25, 2.5, 5 lg, and placebo on top of olodaterol
5 lg (a) and 10 lg (b). -1:00 value is mean of 1 h
pre-treatment and 10 min pre-treatment values. P\0.05
for all tiotropium ? olodaterol versus olodaterol 5 lg in
(a) and versus olodaterol 10 lg in (b). FEV1 forced
expiratory volume in 1 s
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pronounced improvements in trough FEV1 were
observed with the combined tiotropium and
olodaterol doses. Primary end point data were
supported by the FEV1 and FVC profiles from 0
to 6 h. Trough FEV1 was selected as the primary
end point for this study to allow an evaluation
of the effect of the drug combination at the end
of the dosing period and, together with the
Fig. 4 FVC proﬁles after 4 weeks of treatment with
tiotropium 1.25, 2.5, 5 lg, and placebo on top of olodaterol
5 lg (a) and 10 lg (b). -1:00 value is mean of 1 h
pre-treatment and 10 min pre-treatment values. P\0.05
for all tiotropium ? olodaterol versus olodaterol 5 lg in
(a) and versus olodaterol 10 lg in (b). FVC forced vital
capacity














O 5 lg 0.114 (0.029) 0.282 (0.032)
?T 1.25 lg 0.214 (0.029) 0.099 (0.040, 0.159) 0.0010 0.421 (0.032) 0.139 (0.081, 0.197) \0.0001
?T 2.5 lg 0.234 (0.029) 0.120 (0.061, 0.179) \0.0001 0.432 (0.032) 0.150 (0.092, 0.207) \0.0001
?T 5 lg 0.215 (0.029) 0.100 (0.041, 0.160) 0.0010 0.414 (0.032) 0.131 (0.073, 0.189) \0.0001
O 10 lg 0.122 (0.029) 0.277 (0.032)
?T 1.25 lg 0.253 (0.029) 0.131 (0.071, 0.190) \0.0001 0.466 (0.032) 0.189 (0.131, 0.247) \0.0001
?T 2.5 lg 0.253 (0.029) 0.131 (0.072, 0.191) \0.0001 0.456 (0.032) 0.179 (0.121, 0.236) \0.0001
?T 5 lg 0.249 (0.029) 0.127 (0.067, 0.187) \0.0001 0.490 (0.032) 0.213 (0.155, 0.271) \0.0001
AUC0–6 area under the curve from 0 to 6 h, CI conﬁdence interval, FVC forced vital capacity, O olodaterol, SE standard
error, T tiotropium
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FEV1 0 to 6-h profiles, allows investigation of
the 24-h lung function profile.
The free combination of tiotropium ?
olodaterol was well tolerated at all doses in
this trial, with no specific safety concerns or
cardiovascular safety concerns raised. There was
no increase in AEs with tiotropium ? olodaterol
compared to monotherapies and no dose
dependency observed for AEs. The safety of
the combination has subsequently been
assessed in a pooled safety analysis of two
replicate phase III tiotropium ? olodaterol FDC
studies (Study 1237.5: NCT01431274; Study
1237.6: NCT01431287). Tiotropium ?
olodaterol FDC was well tolerated in these
trials, with comparable AE incidence to
monotherapy [13].
This trial was part of a novel approach to
dose finding with drug combinations, in which
the dose response of each component within
the FDC was explored to confirm whether it is
the same as the dose response when used as
monotherapy. The dose response of olodaterol
alone was investigated in olodaterol
dose-finding studies, which identified
olodaterol 5 and 10 lg as the doses to be taken
forward to the phase III trials [14], and the dose
response of tiotropium monotherapy in the
Respimat inhaler has been investigated [15],
with 5 lg performing best and subsequently
licensed in COPD. The present study was not
powered to detect differences between different
combined doses of tiotropium ? olodaterol, but
it was sufficient to identify dose ordering for
































Any AE 35 (32.4) 42 (38.5) 38 (33.6) 35 (32.1) 36 (33.0) 32 (29.1) 37 (33.6) 39 (35.1)
Drug-relateda 2 (1.9) 4 (3.7) 1 (0.9) 4 (3.7) 2 (1.8) 1 (0.9) 2 (1.8) 5 (4.5)
AEs leading to
discontinuation
1 (0.9) 2 (1.8) 2 (1.8) 2 (1.8) 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.9)
Serious AEs 4 (3.7) 1 (0.9) 3 (2.7) 1 (0.9) 2 (1.8) 1 (0.9) 5 (4.5) 0 (0.0)
Fatal 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.8) 0 (0.0) 0 (0.0) 0 (0.0)
Leading to
hospitalization
4 (3.7) 1 (0.9) 3 (2.7) 1 (0.9) 0 (0.0) 1 (0.9) 5 (4.5) 0 (0.0)
AEs with incidence[3%
Nasopharyngitis 11 (10.2) 12 (11.0) 8 (7.1) 3 (2.8) 7 (6.4) 8 (7.3) 4 (3.6) 2 (1.8)
COPD 7 (6.5) 4 (3.7) 4 (3.5) 8 (7.3) 6 (5.5) 7 (6.4) 5 (4.5) 4 (3.6)
Cough 1 (0.9) 4 (3.7) 1 (0.9) 4 (3.7) 0 (0.0) 4 (3.6) 2 (1.8) 3 (2.7)
Dyspnea 4 (3.7) 1 (0.9) 1 (0.9) 3 (2.8) 1 (0.9) 0 (0.0) 2 (1.8) 1 (0.9)
Headache 2 (1.9) 4 (3.7) 2 (1.8) 2 (1.8) 1 (0.9) 2 (1.8) 1 (0.9) 1 (0.9)
AE adverse event, COPD chronic obstructive pulmonary disease, O olodaterol, T tiotropium
a Investigator-deﬁned
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FEV1 responses for the dose combinations.
These data, together with the results of
olodaterol and tiotropium dose-finding studies
and the two other tiotropium ? olodaterol
dose-finding studies, led to tiotropium ?
olodaterol 2.5/5 and 5/5 lg FDCs being
investigated in the phase III program. The
results of this study of the free combinations
of tiotropium ? olodaterol 2.5/5 and 5/5 lg are
consistent with the results from the phase III
trials that were subsequently performed with
FDCs of tiotropium ? olodaterol 2.5/5 and
5/5 lg, and demonstrated similar effect sizes
compared to tiotropium [16].
The results showed that with this drug
combination, it may have been acceptable to
simply use the doses of each agent that are
considered optimal as monotherapies.
However, the preclinical studies had suggested
that there may be some synergistic effect with
the combination of tiotropium ? olodaterol at
sub-optimal doses [17] and this is one of the
reasons why this study was performed. It is not
known whether this effect occurs in humans at
sub-optimal doses, but it does not appear that
the optimal dose of tiotropium ? olodaterol is
any lower than the approved doses of the
monotherapies. This study demonstrated that
the most suitable combination of
tiotropium ? olodaterol was at the licensed
doses of the individual therapies; however,
this result is specific to this combination of
therapies and may not necessarily be the same
for other combinations of therapies.
In addition to the main investigation of lung
function in this study, a number of additional
end points were included in the trial to explore
the effects of the drug combination. The data
presented here demonstrate that rescue
medication use decreased compared to
baseline with all treatments, but the
differences between treatment groups were
small. It is challenging in phase II studies to
investigate effects on symptoms given relatively
low patient numbers, but the results of
subsequent tiotropium ? olodaterol FDC
phase III studies demonstrated that lung
function improvements were translated into
symptom improvements. There were greater
reductions in rescue medication use with
combined therapy than with monotherapies
over 52 weeks in two phase III studies (1237.5;
1237.6) [16]. Physician’s global evaluation
scores improved with all treatments, and
patients generally rated their health as ‘‘a little
better’’ on the patient’s global rating scale, but
the results across treatment arms were similar.
Consistent with the results of the olodaterol
phase III program [7–10], there was little
difference in efficacy between olodaterol 5 and
10 lg in this study. Both tiotropium ?
olodaterol 2.5/5 and 5/5 lg have subsequently
demonstrated efficacy and acceptable
tolerability in large phase III trials
investigating the FDCs in the Respimat inhaler
[16, 18]. The phase III program was designed to
determine whether the improvements in lung
function seen in the phase II trials translated
into long-term benefits in lung function and
improvements in patient-reported outcomes, as
well as investigating the risk:benefit ratio of the
FDCs compared to monotherapies. Two
replicate 12-month studies have demonstrated
improvements in lung function with
tiotropium ? olodaterol FDC compared to
monotherapies at 24 weeks and improvements
in St. George’s Respiratory Questionnaire score
compared to monotherapies (tiotropium ?
olodaterol 5/5 lg) [16].
One potential limitation of the study is that,
because the lower dose of tiotropium was not
available in an FDC, the tiotropium ?
olodaterol doses were administered as
free-dose combinations in separate inhalers.
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However, it should be possible to extrapolate
the results to the FDCs. As the formulations for
the FDC are very similar to those used in the
monotherapies, the differences in
administration are minor (it takes only a little
more time to use two inhalers rather than one)
and compliance with two bronchodilators is
generally relatively high. Another possible
limitation is the lack of a placebo group,
which may have further put the effect sizes
into context. As this was not central to the
primary objectives of the study, and there were
already a large number of treatment arms, it was
not possible. Phase III trials have subsequently
investigated tiotropium ? olodaterol with a
placebo arm [19]. The study also excluded
patients with GOLD 4 COPD; again, these
patients have been included in later phase III
trials [16, 19].
CONCLUSION
Overall, the addition of all tiotropium doses to
olodaterol resulted in improvements in lung
function compared to olodaterol alone after
4 weeks, and incremental increases in FEV1 were
observed with increasing doses of tiotropium on
top of each olodaterol dose. The free
combination of tiotropium and olodaterol was
well tolerated at all doses, with a similar AE
incidence to olodaterol alone.
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